10 November 2026
Linklaters advises Zylox-Tonbridge on acquisition of equity interest in LifeTech Scientific Corporation and new share issuance
Advising firms
Deal team
11 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Oliver Zhong Lead | Linklaters | Partner | capital markets | Not stated |
| Betty Yap | Linklaters | Partner | corporate | Not stated |
| Roger Cheng | Linklaters | Partner | corporate | Not stated |
| Queenie Tong | Linklaters | Partner | corporate | Not stated |
| Jiang Zhao | Linklaters | Not stated | Not stated | Not stated |
| Mori Cheng | Linklaters | Not stated | Not stated | Not stated |
| Peony Leung | Linklaters | Not stated | Not stated | Not stated |
| Yujie Wen | Linklaters | Not stated | Not stated | Not stated |
| Xi Liao | Zhao Sheng Law Firm | Not stated | antitrust | Not stated |
| Larry Zhou | Zhao Sheng Law Firm | Not stated | antitrust | Not stated |
| Joshua Li | not_stated | Not stated | employment law | Not stated |
8 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Zylox-Tonbridge Medical Technology Co., Ltd.Buy-side
- Counterparties
- LifeTech Scientific Corporation (Target)
GL Capital (Joint venture party)